We and others previously demonstrated that Batf3-lineage dendritic cells (DCs), which express the markers CD8α or CD103, act in at least two steps in anti-tumor immunity: 1) spontaneous T cell priming in the tumor-draining lymph node, and 2) recruitment of effector CD8+ T cells to the tumor [1-3]. Here, ITGAE is linked to neoplasm.